Navigation Links
Abbott Offers Aluvia to Thailand in Return for Compulsory Licensing Halt

Abbott Laboratories said this week that it is willing to proceed with the registration of a heat stable version of lopinavir/ritonavir called Aluvia in Thailand if the Thai// government will halt its plans for a compulsory license to allow imports of a generic version from India, and will sell it to the Thai government for $1000 a year.

Abbott has been in dispute with the Thai government since January 2007, when plans for a compulsory license to import lopinavir/ritonavir were first announced by the Thais. Abbott retaliated by withdrawing seven products from drug registration processes in Thailand, including Aluvia.

In February Abbott offered a price cut to $167 a month for Kaletra, the soft-gel capsule version of lopinavir/ritonavir.

Earlier in April Abbott announced that it was cutting the price of Kaletra and Aluvia when registered to $1000 a year in 40 lower middle-income countries following discussions with World Health Organization director-general Margaret Chan. But the company said that its offer would only apply where its patents are respected, a clear warning to the Thai government.

According to the Wall Street Journal, Abbott chief executive Miles White said that the decision to withdraw Aluvia from registration had been driven by “concern that compulsory licensing would be abused ever-more widely, using HIV as an excuse."

But last month Abbott public affairs staff insisted that the company’s action was not related to HIV drugs, but to a lack of respect for `numerous` patents.

Treatment advocates have urged the Thai government not to back down on its compulsory licensing policy.

“The fact that Thailand has been brave enough to issue a compulsory license means that 40 countries are now able to get Kaletra for $1000 a year,” said Paul Cawthorne, head of mission for Médecins sans Frontières in Thailand, speaking during a phone briefing for journalists earlier today.
The Thai government says that negotiations will continue.

A version of lopinavir/ritonavir alleged to be heat-stable was recently launched by the Indian company Emcure. However no data is available on the manufacturer’s website to explain the stablility of Emletra, and the product has not been prequalified by the World Health Organization.

Source-Generef.com'"/>




Related medicine news :

1. Pharmacia may take 51.5 percent Abbott stake
2. Abbott Laboratories to buy Biocompatibles cardiovascular stent business
3. Abbott’s Laboratories R&D Capabilities Questione
4. Abbott Receives CE Mark Certification
5. Abbott to Subsidize Price of HIV Drug
6. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
7. Drug Offers Hope for Alzheimers disease
8. Drug Firm Offers to Donate Smallpox Vaccine
9. fMRI Offers Insight Into An Infants Brain
10. Gel Offers A More Targeted Approach
11. Umbilical Cord Blood Offers Hope For Patients Who Require Bone Marrow Transplants
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: